Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Sep 24, 2026 | clinicaltrials |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06804785 | Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)(HIT-PIRADS) | withdrawn | — | 0 | Northwestern UniversityOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 2 | Aug 19, 2026 | clinicaltrials |
| NCT07655284 | STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy | withdrawn | Phase 3 | 0 | Brigham and Women's HospitalOTHER | 2 | Aug 13, 2026 | clinicaltrials |
| NCT02432378 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial(ROMECO) | withdrawn | N/A | 0 | University Hospital, ToursOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT06185478 | Prostate Diffusion Imaging With Distortion Correction | withdrawn | N/A | 0 | Norfolk and Norwich University Hospitals NHS Foundation TrustOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04149145 | Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer(PARP) | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07624578 | Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study(REIN-TEP PSMA) | withdrawn | N/A | 0 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jun 3, 2026 | clinicaltrials |
| NCT05714826 | Comprehensive Optimization At-time of Radical Cystectomy Intervention(COARC) | withdrawn | N/A | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT07111039 | Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila | withdrawn | N/A | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT01673581 | Shared Decision Making in Low Risk Prostate Cancer | withdrawn | — | 0 | Massachusetts General HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04565496 | Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients(PEM-PRO) | withdrawn | Phase 2 | 0 | IRCCS San RaffaeleOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07237399 | Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM)(TA-P-OLIM) | withdrawn | — | 0 | University Hospital, GhentOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study | withdrawn | Early Phase 1 | 0 | Kousai Bio Co., Ltd.OTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 8, 2026 | clinicaltrials |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | withdrawn | Early Phase 1 | 0 | Thomas HopeOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07541066 | Robotic Telesurgery in Urology | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07060365 | A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | AstraZenecaINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer(exBOND) | withdrawn | Phase 2 | 0 | CG Oncology, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06282185 | SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy(Superman) | withdrawn | N/A | 0 | Canisius-Wilhelmina HospitalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | withdrawn | N/A | 0 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04243473 | Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07211204 | Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population | withdrawn | N/A | 0 | Timser SAPI de CVINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05014295 | Patient Recall of Cancer Screening and Diagnosis | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Feb 24, 2026 | clinicaltrials |
| NCT03027986 | Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy(PROTOMEN) | withdrawn | N/A | 0 | University Hospital, RouenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05487859 | Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT05512260 | Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs(BESTa) | withdrawn | N/A | 0 | Karolinska InstitutetOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | withdrawn | N/A | 0 | University of OklahomaOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT02554344 | Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs) | withdrawn | Early Phase 1 | 0 | Baylor Research InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Thera SolutionsINDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC(NeoPSMA) | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03274778 | Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells | withdrawn | N/A | 0 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Oct 21, 2025 | clinicaltrials |
| NCT04645810 | A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence | withdrawn | N/A | 0 | University of RochesterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05483023 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 14, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials